This site is intended for Healthcare Professionals only.

Esperion Therapeutics’ ‘bempedoic acid’ shows potential to reduce cardiac illnesses, reveals GlobalData

Date:

Share post:

Esperion Therapeutics’ non-statin therapy “bempedoic acid” has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company.

As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData.

According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025.

Neha Myneni, Pharma Analyst at GlobalData, comments: “Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space.”

Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

CETPi inhibitors are example of a failed class of therapy for statin-intolerant patients. Till date, four CETPi inhibitors (Pfizer’s torcetrapib; Merck’s anacetrapib; Roche’s dalcetrapib; and Lilly’s evacetrapib) reached Phase III cardiovascular outcome trials. However, further development of all these molecules was discontinued due to their insufficient cardiovascular benefit for regular use.

Myneni concludes: “With a potential to address about 100,000–500,000 statin-intolerant patients in Australia, bempedoic acid, however, may not be considered an alternate to statin therapy at this juncture with only moderate improvement in LDL lowering efficacy and reduction in cardiovascular risk. Further trials comparing the efficacy of bempedoic acid head-on with statins or other established therapies in future could prove its efficacy in LDL treatment.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

How Bioprocess Containers Improve Vaccine Transportation

Have you ever wanted to know how vaccines are sent out from a lab to your doctor’s office...

Celebrating the Festival of Lights: Diwali messages from pharmacy leaders

As the country celebrates Diwali, symbolising the victory of good over evil and of light over darkness, Pharmacy...

Autumn Budget 2024: Pharmacies ‘deeply worried’ about National Insurance rise

No mention of action to halt pharmacy closure in the Autumn Budget upsets community pharmacies The new Labour...

Autumn Budget 2024: What it has for retail businesses?

The new Labour government’s first Budget reduces business rates and allocates £1.9 billion to support small businesses and...